BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Somatoprim: Interim Phase Ib data

Interim data from a Phase Ib trial in healthy male volunteers showed that multiple ascending-doses of Somatoprim with and without octreotide led to no serious adverse events. Reported adverse events were generally mild to moderate and transient. The maximum tolerated dose (MTD) was not reached....

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >